https://www.pharmacytimes.com/view/fda-approves-fidanacogene-elaparvovec-dzkt-as-one-time-gene-therapy-for-adults-with-hemophilia-b
FDA Approves Fidanacogene Elaparvovec-dzkt as One-Time Gene Therapy for Adults With Hemophilia B |...
Oct 12, 2026 - The 1-time treatment may be a better alternative for patients who don’t want to undergo frequent doses of standard of care intravenous factor IX infusions.
fidanacogene elaparvovecas onefor adultshemophilia bfda
https://www.geneediting.com/clinical-trials/NCT05568719/
NCT05568719: Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in...
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia...
giroctocogene fitelparvovecfidanacogene elaparvovecsafetyeffectiveness